Varicella Active Surveillance Project

自1994年以来，洛杉矶县卫生服务部的急性传染病控制部门通过其在加利福尼亚州羚羊谷的水痘主动监测项目（VASP）与CDC合作。我们建议继续对水痘和带状疱疹进行积极监测，并将该项目扩大到圣克拉里塔市，使人口增加到50万以上。我们计划保持对水痘和HZ的积极监测，规范病例核查，完成病例报告，记录水痘疫苗使用情况，并继续监测数据评估。 从1994年至今，VASP在各种流行病学项目中与其他水痘监测研究中心合作。我们计划进行两项应用流行病学研究计划。第一个项目将评估是否主动在学校接种水痘疫苗的易感学生与标准做法转介儿童到他们的医疗提供者一旦第一个水痘病例被证实将减少随后的水痘病例的数量。第二个项目将分析带状疱疹住院从1992年至2007年，使用ICD-9出院代码表示的前8个出院诊断。我们将回顾病历，分析水痘疫苗广泛使用前后HZ发病率的趋势。 此外，我们正在申请对轮状病毒感染（RVI）进行监测。我们将利用现有的VASP基础设施，并在AV和圣克拉里塔市开发RVI主动监视站点。我们将在主动监测中心建立每两周一次的RVI数据收集，并将确定诊所、急诊室和住院环境中RVI的发生率。我们将通过使用ICD-9 RVI腹泻出院诊断代码计算医院和急诊室中RVI腹泻的发生率来评估我们的系统。当新的RV疫苗Rotashield发布时，我们将测量疫苗使用情况及其对RVI发病率的影响。

Since 1994 the County of Los Angeles Department of Health Services' Acute Communicable Disease Control has collaborated with CDC through its Varicella Active Surveillance Project (VASP) in Antelope Valley, CA. We propose to continue varicella and herpes zoster (HZ) active surveillance and extend the project to the city of Santa Clarita to increase the population to over 500,000. We plan to maintain active surveillance for both varicella and HZ, standardize case verification, complete case reports, document varicella vaccine usage, and continue surveillance data evaluation. VASP has collaborated with other varicella surveillance study sites in various epidemiological projects from 1994-present. We plan to conduct two applied epidemiologic research projects. The first project will evaluate if proactive on-site school varicella vaccination of susceptible students versus the standard practiceof referring children to their medical provider once the first varicella case is confirmed will decrease number of subsequent varicella cases. The second project will analyze zoster hospitalizations from 1992-2007, utilizing ICD-9 discharge codes denoted with the first 8 hospital discharge diagnoses. We will review medical charts and analyze HZ rates for incidence trends pre- and post-widespread varicella vaccine usage. Additionally, we are applying to conduct surveillance for rotavirus infection (RVI). We will utilize the existing VASP infrastructure and develop sites for RVI active surveillance throughout AV and the city of Santa Clarita. We will establish biweekly RVI data collection at active surveillance sites and will determine the incidence of RVI in clinic, emergency room, and inpatient settings. We will evaluate our system by calculating incidence of diarrhea due to RVI in hospital and emergency room utilizing ICD-9 discharge diagnosis codes for diarrhea due to RVI. When the new RV vaccine, Rotashield, is released, we will measure vaccine usage and its impact on RVI incidence.